Disclosed are compounds which bind VLA-4. Certain of these compounds also
inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4.
Such compounds are useful in the treatment of inflammatory diseases in a mammalian
patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS
dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation,
tumor metastasis and myocardial ischemia. The compounds can also be administered
for the treatment of inflammatory brain diseases such as multiple sclerosis.
